Healing of diabetic foot ulcers and pressure ulcers with human skin equivalent: A new paradigm in wound healing

Archives of Surgery

Volumn 135, Issue 6, 2000, Pages 627-634

  Brem, Harold ^a   Balledux, Jeroen ^a   Bloom, Tamir ^a   Kerstein, Morris D ^a   Hollier, Larry ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DEBRIDEMENT; DIABETIC FOOT; DISEASE COURSE; EPITHELIZATION; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; SKIN GRAFT; WOUND CONTRACTION; WOUND DRAINAGE; WOUND HEALING; WOUND INFECTION;

EID: 0034089949     PISSN: 00040010     EISSN: None     Source Type: Journal    
DOI: 10.1001/archsurg.135.6.627     Document Type: Article

References (54)

1. Allman RM. Pressure ulcer prevalence, incidence, risk factors, and impact. Clin Geriatr Med. 1997;13:421-436.
2. Nelzen O, Bergqvist D, Lindhagen A, et al. Chronic leg ulcers: an underestimated problem in primary health care among elderly patients. J Epidemiol Community Health. 1991;5:184-191.
3. Harris MI, Cowie CC, Reiber G, Boyko E, Stern M, Bennett P, eds. Diabetes in America. Washington, DC: US Government Printing Office; 1995.
4. Centers for Disease Control and Prevention. National Diabetes Fact Sheet: National Estimates and General Information on Diabetes in the United States. Rev ed. Atlanta, Ga: US Dept of Health and Human Services, Centers for Disease Control and Prevention: 1998.
5. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation. Diabetes Care. 1990;13:513-521.
6. Reiber GE, Boyko EJ, Smith DG. Lower extremity foot ulcers and amputations in diabetes. In: Harris MI, Cowie CC, Reiber G, Boyko E, Stern M, Bennett P, eds. Diabetes in America. Washington, DC: US Government Printing Office; 1995: 409-428.
7. Eckman MH, Greenfield S, Mackey WC, et al. Foot infections in diabetic patients: decision and cost-effectiveness analyses. JAMA. 1995;273:712-720.
8. O'Brien SP, Gahtan V, Wind S, Kerstein MD. What is the paradigm: hospital or home health care for pressure ulcers? Am Surg. 1999;65:303-306.
9. Allman R. Pressure ulcer prevalence, incidence, risk factors, and impact. In: Thomas DR, Allman RM, eds. Clinics in Geriatric Medicine. Philadelphia, Pa: WB Saunders Co; 1997:421-436
10. Moody BL, Fanale JE, Thompson M, Vaillancourt D, Symonds G, Bonasoro C. Impact of staff education on pressure ulcer sore development in elderly hospitalized patients. Arch Intern Med. 1988;148:2241-2243.
11. Scheckler WE, Peterson PJ. Infections and infection control among residents of eight rural Wisconsin nursing homes. Arch Intern Med. 1986;146:1981-1984.
12. Shannon ML, Skorga P. Pressure ulcer prevalence in two general hospitals. Decubitus. 1989;2:38-43.
13. Pase MN. Pressure relief devices, risk factors, and development of pressure ulcers in elderly patients with limited mobility. Adv Wound Care. 1994;7:38-42.
14. Brandeis GH, Morris JN, Nash DJ, Lipsitz LA. The epidemiology and natural history of pressure ulcers in elderly nursing home residents. JAMA. 1990;264: 2905-2909.
15. Allman RM. Pressure ulcers among the elderly. N Engl J Med. 1989;320:850-853.
16. Allman RM. Outcomes in prospective studies and clinical trials. Adv Wound Care. 1995;8(suppl):61-64.
17. Nathan CF. Secretory products of macrophages. J Clin Invest. 1987;79:319-326.
18. Brem H, Folkman J. Angiogenesis and basic fibroblast growth factor during wound healing. In: Brighton CT, Friedlander GE, Lane JM, eds. Bone Formation and Repair. Rosemont, III: American Academy of Orthopedic Surgeons; 1994:213-222.
19. Lazarus GS, Cooper DM, Knighton DR, et al. Definitions and guidelines for assessment of wounds and evaluation of healing. Arch Dermatol. 1994;130:489-493.
20. Mostow EN. Diagnosis and classification of chronic wounds. Clin Dermatol. 1994; 12:3-9.
21. Steed DL. Foundations of good care. Am Surg. 1998;176(suppl 2A):20S-25S.
22. Knight EV, Oldham JW, Mohler MA, Liu S, Dooley J. A review of nonclinical toxicology studies of becaplermin (rhPDGF-BB). Am Surg. 1998;176(suppl 2A):55S-60S.
23. LeGrand EK. Preclinical promise of becaplermin (rhPDGF-BB) in wound healing. Am Surg. 1998;176(suppl 2A):26S-38S.
24. Muhart M, McFalls S, Kirsner RS, et al. Behavior of tissue-engineered skin: a comparison of a living skin equivalent, autograft, and occlusive dressing in human donor sites. Arch Dermatol. 1999;135:913-918.
25. Eaglstein WH, Iriondo M, Laszlo K. A composite skin substitute (Graftskin) for surgical wounds: a clinical experience. Dermatol Surg. 1995;21:839-843.
26. Falabella AF, Schachner LA, Valencia IC, Eaglstein WH. The use of tissue-engineered skin (Apligraf) to treat a newborn with epidermolysis bullosa. Arch Dermatol. 1999;135:1219-1222.
27. Sabolinski ML, Alvarez O, Auletta M, Mulder G, Parenteau NL. Cultured skin as a "smart material" for healing wounds: experience in venous ulcers. Biomaterials. 1996;17:311-320.
28. Falanga V. How to use Apligraf to treat venous ulcers. Skin Ageing. 1999;25:30-36.
29. Falanga V, Margolis D, Alvarez O, et al. Rapid healing of venous ulcers and lack of clinical rejection with allogeneic cultured human skin equivalent. Arch Dermatol. 1998;134:293-300.
30. Parenteau N. Skin: the first tissue-engineered products. Sci Am. 1999;280:83-84.
31. Fiala TG, Andrew Lee WP, Hong HZ, May JW Jr. Bacterial clearance capability of living skin equivalent, saline dressing, and xenograft dressing in the rabbit. Ann Plast Surg. 1993;30:516-519.
32. Falanga V, Sabolinski M. A bilayered skin construct (Apligraf) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Generation. 1999;7: 201-207.
33. Parentau NL, Nolte CM, Bilbo P, et al. Epidermis generated in vitro: practical considerations and applications. J Cell Biochem. 1991;45:245-251.
34. Bell E, Rosenberge M, Kemp P, et al. Recipes for reconstituting skin. J Biomech Eng. 1991;113:113-119.
35. Zieskeh JD, Mason VS, Wasson ME, et al. Basement membrane assembly and differentiation of cultured corneal cells: importance of culture environment and endothelial cell interaction. Exp Cell Res. 1994;214:621-633.
36. Maklebust J. Pressure ulcer assessment. In: Thomas DR, Allman RM, eds. Clinics in Geriatric Medicine: Pressure Ulcers. Philadelphia, Pa: WB Saunders Co: 1997:455-473.
37. Pruitt BA Jr, McManus AT, Kim SH, Goodwin CW. Burn wound infections: current status. World J Surg. 1998;22:133-145.
38. Steed DL, Donohue D, Webster MW, et al. Effect of extensive debridement and treatment on the healing of diabetic foot ulcers. J Am Coll Surg. 1996;183:61-64.
39. Proceedings of the 5th Annual Meeting of the European Tissue Repair Society, Padova, Italy, August 30-September 2, 1995 [abstract]. Wound Repair Regen. 1995;3:359.
40. Pham HT, Rosenblum BI, Lyons TE, et al. Evaluation of a human skin equivalent for the treatment of diabetic foot ulcers in a prospective randomized, clinical trial, Wounds. 1999;11:79-86.
41. Levenson SM, Demetriou AA. Metabolic factors. In: Cohen IK, Diegelmann RF, Lindblad WJ, eds. Wound Healing Biochemical and Clinical Aspects. Philadelphia, Pa: WB Saunders Co: 1992:248-273.
42. Pecoraro RE, Reiber GE, Burgess EM. Pathways to diabetic limb amputation: basis for prevention. Diabetes Care. 1990;13:513-521.
43. Smiell JN, and the Becaplermin Study Group. Clinical safety of becaplermin (rh-PDGF-BB) gel. Am J Surg. 1998;176(suppl 2A):68S-73S.
44. El Saghir NS, Bizri AR, Shabb NS, Husami TW, Salem Z, Shamseddine AI. Pressure ulcer accelerated healing with local injections of granulocyte macrophage-colony stimulating factor. J Infect. 1997;35:179-182.
45. Arnold F, O'Brien J, Cherry G, Granulocyte monocyte-colony stimulating factor as an agent for wound healing: a study evaluating the use of local injections of a genetically engineered growth factor in the management of wounds with a poor healing prognosis. J Wound Care. 1995;4:400-402.
46. Marques da Costa R, Jesus MF, Aniceto C, Mendes M. Double-blind randomized placebo-controlled trial of the use of granulocyte-macrophage colony-stimulating factor in chronic leg ulcers. Am J Med. 1997;173:165-168.
47. Wheeler G, Brodle GN. GM-CSF and wound healing [letter]. Med J Aust. 1998; 168:580.
48. Jaschke E, Zabernigg A, Gattringer C. Recombinant human granulocyte-macrophage colony-stimulating factor applied locally in low doses enhances healing and prevents recurrence of chronic venous ulcers. Int J Dermatol. 1999;38: 380-386.
49. Remes K, Ronnemaa T. Healing of chronic leg ulcers in diabetic necrobiosis lipoidica with local granulocyte-macrophage colony stimulating factor treatment. J Diabetes Complications. 1999;13:115-118.
50. Jyung RW, Wu L, Pierce GF. Granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor: differential action on incisional wound healing. Surgery. 1994;115:325-334.
51. Akbari CM, LoGerfo FW. Diabetes and peripheral vascular disease. J Vasc Surg. 1999;24:373-384.
52. LoGerfo FW, Coffman JD. Vascular disease of the lower extremities in diabetes mellitus. Endocr Metab Clin North Am. 1996;30:499-508.
53. Berceli SA, Chan AK, Pomposeli FB, et al. Efficacy of dorsal pedal artery bypass in limb salvage for ischemic heel ulcers. J Vasc Surg. 1999;30:499-508.
54. LoGerfo FW, Coffman JD. Vascular and microvascular disease of the foot in diabetes. N Engl J Med. 1984;311:1615-1619.